Carcinoma, Non-Small-Cell Lung
Conditions
Keywords
non small cell lung cancer, NSCLC, Platinum
Brief summary
This Study evaluate the effect of Polymorphism in the Excision repair cross-complementing group 5 (ERCC5) (rs1047768 and rs751402) gene on the clinical outcome of Platinum-based regimens used in the treatment of Non-Small Cell Lung Cancer (NSCLC) patients
Interventions
None listed
Sponsors
Ain Shams University
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Newly diagnosed with immunohistochemically and pathologically confirmed non-small cell lung cancer (NSCLC). 2. Eastern Cooperative Oncology Group performance status (ECOG PS) = 0-2. 3. Chemotherapy naïve. 4. Age \>18 years. 5. Adequate bone marrow reserve
Exclusion criteria
1. Presence of Central nervous system(CNS) metastases. 2. Inadequate liver function 3. Inadequate renal function 4. Serious comorbid systemic disorder incompatible with the study. 5. Pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival (PFS) | From the date of starting the chemotherapy until the date of documented disease progression or date of death from any cause assessed up to 12 months | It's defined as the time from day 1 of chemotherapy to the day of documented disease progression or death from any cause. |
Countries
Egypt
Contacts
Primary Contactdemonstrator of clinical pharmacy
Outcome results
None listed